FOR IMMEDIATE RELEASE

PlantForm growing ‘made-in-Ontario innovation’

GUELPH, Ont., Sept. 26, 2013—Ontario NDP Leader Andrea Horwath met with PlantForm Corporation management and staff, and toured the company’s research greenhouse today. Her visit came as PlantForm scales up production of its first oncology drug, a biosimilar version of Herceptin® (trastuzumab) for breast cancer, in preparation for Phase 1 clinical trials.

“Our meeting with Ms. Horwath was an excellent opportunity to discuss how PlantForm technology will lead to more affordable medications for cancer and other diseases,” said Dr. Don Stewart, President and CEO. “Our aim is to increase access to these life-saving biopharmaceuticals to reduce the financial burden on patients and health-care systems around the world.”

“To help our province’s economy grow and thrive, we need to encourage the kind of made-in-Ontario innovation happening at companies like Guelph’s PlantForm,” Horwath said.

PlantForm Corporation’s low-cost, plant-based manufacturing platform is designed to produce a wide range of monoclonal antibodies, protein drugs and vaccines for cancer and other critical illnesses. The company’s pipeline also includes biosimilar versions of two additional antibody
drugs for cancer; antibodies for the treatment of human immunodeficiency virus (HIV), funded by the Canadian HIV Vaccine Initiative; and an enzyme to protect against nerve agent exposure, under contract with the U.S. Defense Advanced Research Projects Agency.

Projected revenue is more than $120 million by 2017.

-30-

For more information, please contact:
Don Stewart
President and CEO
don.stewart@plantformcorp.com
(416) 452-7242

Stacey Curry Gunn
Director of Communications
stacey.curry.gunn@plantformcorp.com
(519) 827-1131